Radiotherapy
Comparison of simultaneous integrated boost and late course boost intensity-modulated radiation therapy in the treatment of esophageal carcinoma
Wenwen Bai, Liyuan Fu, Jing Li, Ruohui Zhang, Chanjun Zhen, Rui Zhang, Shuoshuo Wang, Ming Liu, Xueying Qiao
Published 2018-04-25
Cite as Chin J Radiol Med Prot, 2018, 38(4): 258-264. DOI: 10.3760/cma.j.issn.0254-5098.2018.04.004
Abstract
ObjectiveTo analyze and compare the outcomes of esophageal carcinoma treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) and late course boost intensity-modulated radiation therapy (LCB-IMRT).
MethodsWe retrospectively analyzed 128 patients with esophageal squamous cell carcinoma who were treated with SIB-IMRT or LCB-IMRT at the fifth department of radiation oncology in our hospital, from January 2009 to August 2015. Propensity score matching analysis was used to balance the variables differences in the two groups. Survival, failure patterns and toxicities were observed and compared between the two groups.
Resultsone hundred and eleven patients were finally included after propensity scores matching. The l-, 3- and 5- year local control rates and survival rates were 83.6% vs. 81.7%, 70.8% vs. 46.3% and 66.0% vs. 38.2% in the whole group, respectively. The 1-, 3- and 5-year local control rates of SIB-IMRT and LCB-IMRT group were 81.6% vs. 88.0%, 72.3% vs. 67.6% and 68.5% vs. 60.8%, respectively (P>0.05). The 1-, 3- and 5-year survival rates of SIB-IMRT and LCB-IMRT group were 81.3% vs. 82.4%, 51.7% vs. 36.7% and 45.8% vs. 26.7%, respectively (P>0.05). There was no statistical difference between the two group in ≥grade 3 toxicities (P>0.05). There were 40 (36.0%) patients result in treatment failure in all. The treatment failure rates in SIB-IMRT and LCB-IMRT group were 33.8% (26/77) vs. 41.2%(14/34), respectively (P>0.05). The local failure accounted for 65.0% (26/40) of all treatment-related failures.
ConclusionsThe toxicities of esophageal squamous cell carcinoma treated with SIB-IMRT and LCB-IMRT have no significant differences and were well tolerated. There were no significant differences in local control rates and survival rates between the two groups. However, SIB-IMRT had better trend than LCB-IMRT. Given SIB-IMRT’s convenient manipulation, it could be a better choice in the treatment of advanced esophageal carcinoma.
Key words:
Esophageal neoplasms; Radiotherapy; Simultaneous integrated boost intensity-modulated radiation therapy /SIB-IMRT; Late course boost to primary tumor with intensity-modulated radiation therapy /LCB-IMRT; Efficacy
Contributor Information
Wenwen Bai
Department of Radiation Oncology, Fourth Hospital of Hebei University, Shijiazhuang 050011, China
Liyuan Fu
Jing Li
Ruohui Zhang
Chanjun Zhen
Rui Zhang
Shuoshuo Wang
Ming Liu
Xueying Qiao
